Protocol Ledger

NCT03836716 · Phase III · TERMINATED

Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial

Interventional Phase III clinical trial protocol NCT03836716 sponsored by ZevraDenmark in Neurology, Psychiatry, and Pain, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2019-09-19 Enrollment: 120 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03836716
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)120 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03836716
Protocol FieldVerified Registry Value
NCT IdentifierNCT03836716
Consolidated Lead SponsorZevraDenmark
Therapeutic Condition CohortNeurology, Psychiatry, and Pain
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment120 participants (ACTUAL)
Registered Start Date2019-09-19
WhyStopped ClassificationLack of Efficacy / Futility

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Neurology, Psychiatry, and Pain Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI